AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
NEW YORK -- The switch of Schering-Plough Corp.'s Claritin from prescription to over-the-counter (O-T-C) status is shaking up the allergy category in more ways than one.
One unexpected result of the move is that some consumers may actually be paying more for the product as a result of the switch, because the nonsedating antihistamine (NSA) is no longer covered by health plans.
Some plans have also started charging higher copayments for such products as Aventis SA's Allegra and Pfizer Inc.'s Zyrtec, both of which are still on patent protection and are available only with a prescription.
Meanwhile California regulators have weighed in, warning health plans last month not to terminate coverage of prescription medication just because a similar drug is available as an O-T-C. Health plans that stop covering such NSAs as Allegra, Zyrtec and Schering-Plough's Clarinex would do so against the state's advice.
The advisory bulletin applies broadly to all categories of drugs, including heartburn remedies known as proton pump inhibitors. Procter & Gamble Co. is preparing a nonprescription version of AstraZeneca's Prilosec.
Consumers buying NSAs, meanwhile, have more choices than ever. Wyeth Consumer Healthcare has begun selling Alavert, a nonprescription allergy medicine containing loratadine, the active ingredient in Claritin.
Wyeth is advertising Alavert ...
Source: HighBeam Research, Claritin switch has deeper implications. (Merchandising).